I'm not looking to make game-changing observations by checking in on different sector weights. That said, it's the pharmaceutical and biotech ETFs that have done most of the heavy lifting. What's more, if you dig even deeper, assets with relatively moderate risk and high yield -- dividends, REITs, partnerships, utilities -- have been the true superstars in the 11/8/10 to 11/7/11 period.
Disclosure Statement: ETF Expert is a website that makes the world of ETFs easier to understand. Gary Gordon, Pacific Park Financial and/or its clients may hold positions in ETFs, mutual funds and investment assets mentioned. The commentary does not constitute individualized investment advice. The opinions offered are not personalized recommendations to buy, sell or hold securities. At times, issuers of exchange-traded products compensate Pacific Park Financial or its subsidiaries for advertising at the ETF Expert website. ETF Expert content is created independently of any advertising relationships. You may review additional ETF Expert at the site.

If you liked this article you might like

Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns

2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap

How to Know if You Are Really a 'Value' Investor

General Dynamics Makes Military Vehicle Push; Sara Lee Spins 'Dough'<BRACKET>

General Dynamics Makes Military Vehicle Push; Sara Lee Spins 'Dough'

5 Health Care Funds for a Healthy Portfolio

5 Health Care Funds for a Healthy Portfolio